Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 26, Issue , 2015, Pages v100-v107

  Robak, T ^a   Matutes, E ^b   Catovsky, D ^c   Zinzani, P L ^d   Buske, C ^e  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ALPHA INTERFERON; B RAF KINASE; BENDAMUSTINE; CLADRIBINE; COTRIMOXAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRUTINIB; MOXETUMOMAB PASUDOTOX; PENTOSTATIN; PROTEIN P53; RITUXIMAB; VEMURAFENIB;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER STAGING; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG RESPONSE; FLOW CYTOMETRY; FOLLOW UP; HAIRY CELL LEUKEMIA; HERPES SIMPLEX; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PNEUMOCYSTOSIS; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETREATMENT; SPLENECTOMY; SPLENOMEGALY; TERATOGENICITY; LEUKEMIA, HAIRY CELL; PATHOLOGY;

HUMANS; LEUKEMIA, HAIRY CELL;

EID: 84941647729     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv200     Document Type: Article

References (72)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-1403.
2. Morton LM, Wang SS, Devesa SS et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107: 265-276.
3. Grever MR, Blachly JS, Andritsos LA. Hairy cell leukemia: update on molecular profiling and therapeutic advances. Blood Rev 2014; 28: 197-203.
4. Swerdlow SH, Campo E, Harris NL et al. World Health Organization (WHO) Classification of Tumours: Pathology and Genetics of Haematopoietic and Lymphatic Tissues. 4th edition. Lyon, France: IARC Press, 2008.
5. Del Giudice I, Matutes E, Morilla R et al. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica 2004; 89: 303-308.
6. Matutes E. Immunophenotyping and differential diagnosis of hairy cell leukemia. Hematol Oncol Clin North Am 2006; 20: 1051-1063.
7. Pillai V, Pozdnyakova O, Charest K et al. CD200 flow cytometric assessment and semiquantitative immunohistochemical staining distinguishes hairy cell leukemia from hairy cell leukemia-variant and other B-cell lymphoproliferative disorders. Am J Clin Pathol 2013; 140: 536-543.
8. Andrulis M, Penzel R, Weichert W et al. Application of a BRAF V600E mutationspecific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol 2012; 36: 1796-1800.
9. Hockley SL, Giannouli S, Morilla A et al. Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma provided by the analysis of their IGH rearrangements and somatic hypermutation patterns. Br J Haematol 2010; 148: 666-669.
10. Forconi F, Sozzi E, Cencini E et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behaviour. Blood 2009; 114: 4696-4702.
11. Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009; 114: 4687-4695.
12. Tiacci E, Trifonov V, Schiavoni G et al. BRAF mutations in hairy cell leukemia. N Engl J Med 2011; 364: 2305-2315.
13. Hockley SL, Else M, Morilla A et al. The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma. Br J Haematol 2012; 158: 347-354.
14. Mercieca J, Puga M, Matutes E et al. Incidence and significance of abdominal lymphadenopathy in hairy cell leukaemia. Leuk Lymphoma 1994; 14(Suppl. 1): 79-83.
15. Mercieca J, Matutes E, Emmett E et al. 2-chlordeoxyadenosine in the treatment of hairy cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy. Br J Haematol 1996; 93: 409-411.
16. Else M, Dearden CE, Matutes E et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009; 145: 733-740.
17. Grever MR. How I treat hairy cell leukemia. Blood 2010; 115: 21-28.
18. Cornet E, Delmer A, Feugier P et al. Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia. Ann Hematol 2014; 93: 1977-1983.
19. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92: 1918-1926.
20. Cheson BD, Sorensen JM, Vena DA et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998; 16: 3007-3015.
21. Robak T, Blasińska-Morawiec M, Krykowski E et al. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymphoma 1996; 22: 107-111.
22. Robak T, Jamroziak K, Gora-Tybor J et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 2007; 109: 3672-3675.
23. Zenhäusern R, Schmitz SF, Solenthaler M et al. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leuk Lymphoma 2009; 50: 1501-1511.
24. von Rohr A, Schmitz SF, Tichelli A et al. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann Oncol 2002; 13: 1641-1649.
25. Lauria F, Cencini E, Forconi F. Alternative methods of cladribine administration. Leuk Lymphoma 2011; 52(Suppl. 2): 34-37.
26. Dearden CE, Else M, Catovsky D. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma 2011; 52(Suppl. 2): 21-24.
27. Flinn IW, Kopecky KJ, Foucar MK et al. Long-term follow-up of remission duration, mortality and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000; 96: 2981-2986.
28. Grever M, Kopecky K, Foucar MK et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995; 13: 974-982.
29. Habermann TM, Rai K. Historical treatments of in hairy cell leukemia, splenectomy and interferon: past and current uses. Leuk Lymphoma 2011; 52(Suppl. 2): 18-20.
30. Anonymous. Consensus resolution: proposed criteria for evaluation of response to treatment in hairy cell leukemia. Leukemia 1987; 1: 405.
31. Jones G, Parry-Jones N, Wilkins B et al. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant. Br J Haematol 2012; 156: 186-195.
32. Naik RR, Saven A. My treatment approach to hairy cell leukemia. Mayo Clin Proc 2012; 87: 67-76.
33. Zinzani PL, Pellegrini C, Stefoni V et al. Hairy cell leukemia: evaluation of the longterm outcome in 121 patients. Cancer 2010; 116: 4788-4792.
34. Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody in the treatment of hairy cell leukaemia. Br J Haematol 2001; 115: 609-611.
35. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003; 102: 810-813.
36. Forconi F, Toraldo F, Sozzi E et al. Complete molecular remission induced by concomitant cladribine-rituximab treatment in a case of multi-resistant hairy cell leukemia. Leuk Lymphoma 2007; 48: 2441-2443.
37. Else M, Dearden CE, Matutes E et al. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma 2011; 52(Suppl. 2): 75-78.
38. Ravandi F, O'Brien S, Jorgensen J et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 2011; 118: 3818-3823.
39. Else M, Osuji N, Forconi F et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer 2007; 110: 2240-2247.
40. Seymour JF, Estey EH, Keating MJ, Kurzrock R. Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia 1995; 9: 929-932.
41. Hoffman MA. Interferon-alpha is a very effective salvage therapy for patients with hairy cell leukemia relapsing after cladribine: a report of three cases. Med Oncol 2011; 28: 1537-1541.
42. Gerrie AS, Zypchen LN, Connors JM. Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. Blood 2012; 119: 1988-1991.
43. Burotto M, Stetler-Stevenson M, Arons E et al. Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clin Cancer Res 2013; 19: 6313-6321.
44. Kreitman RJ, Tallman MS, Robak T et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012; 30: 1822-1828.
45. Tiacci E, De Carolis L, Zinzani PL et al. Vemurafenib is safe and highly active in hairy cell leukemia patients refractory to or relapsed after purine analogs: a phase-2 Italian clinical trial. Haematologica 2014; 99(s1): Abstract S696.
46. Samuel J, Macip S, Dyer MJ. Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med 2014; 370: 286-288.
47. Sivina M, Kreitman RJ, Arons E et al. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br J Haematol 2014; 166: 177-188.
48. Jansen J, Hermans J. Splenectomy in hairy cell leukemia: a retrospective multicenter analysis. Cancer 1981; 47: 2066-2076.
49. Davies JM, Barnes R, Milligan D; British Committee for Standards in Haematology. Working Party of the Haematology/Oncology Task Force. Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Clin Med 2002; 2: 440-443.
50. Zinzani PL, Bonifazi F, Pellegrini C et al. Hairy cell leukemia: allogeneic transplantation could be an optimal option in selected patients. Clin Lymphoma Myeloma Leuk 2012; 12: 287-289.
51. Kiyasu J, Shiratsuchi M, Ohtsuka R et al. Achievement of complete remission of refractory hairy cell leukemia by rituximab progressing after allogeneic hematopoietic stem cell transplantation. Int J Hematol 2009; 89: 403-405.
52. Stiles GM, Stanco LM, Saven A, Hoffmann KD. Splenectomy for hairy cell leukemia in pregnancy. J Perinatol 1998; 18: 200-201.
53. Orlowski RZ. Successful pregnancy after cladribine therapy for hairy cell leukemia. Leuk Lymphoma 2004; 45: 187-188.
54. Baer MR, Ozer H, Foon KA. Interferon-alpha therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia. Br J Haematol 1992; 81: 167-169.
55. Adeniji BA, Fallas M, Incerpi M et al. Laparoscopic splenectomy for hairy cell leukemia in pregnancy. Case Rep Med 2010; 2010: 136823.
56. Daver N, Nazha A, Kantarjian HM et al. Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options. Clin Lymphoma Myeloma Leuk 2013; 13: 86-89.
57. Saven A, Burian C, Adusumalli J, Koziol JA. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood 1999; 93: 2471-2477.
58. Treleaven J, Gennery A, Marsh J et al. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. Br J Haematol 2011; 152: 35-51.
59. Robak T. Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev 2011; 37: 3-10.
60. Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol 2003; 16: 41-56.
61. Narat S, Gandla J, Dogan A, Mehta A. Successful treatment of hairy cell leukemia variant with rituximab. Leuk Lymphoma 2005; 46: 1229-1232.
62. Yoshida T, Mihara K, Sugihara S et al. Splenectomy followed by administration of rituximab is useful to treat a patient with hairy cell leukemia-variant. Ann Hematol 2013; 92: 711-713.
63. Kreitman RJ, Wilson W, Calvo KR et al. Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia. Clin Cancer Res 2013; 19: 6873-6881.
64. Telek B, Batár P, Udvardy M. Successful alemtuzumab treatment of a patient with atypical hairy cell leukaemia variant. Orv Hetil 2007; 148: 1805-1807.
65. Zinzani PL, Lauria F, Buzzi M et al. Hairy cell leukemia variant: A morphologic, immunologic and clinical study of 7 cases. Haematologica 1990; 75: 54-57.
66. Busemann C, Schüler F, Krüger W et al. Late extramedullary relapse after allogeneic transplantation in a case of variant hairy cell leukaemia. Bone Marrow Transplant 2010; 45: 1117-1118.
67. Uppal G, Ly V, Wang ZX et al. The utility of BRAF V600E mutation-specific antibody VE1 for the diagnosis of hairy cell leukemia. Am J Clin Pathol 2015; 143: 120-125.
68. Brown NA, Betz BL, Weigelin HC et al. Evaluation of allele-specific PCR and immunohistochemistry for the detection of BRAF V600E mutations in hairy cell leukemia. Am J Clin Pathol 2015; 143: 89-99.
69. Wang XJ, Kim A, Li S. Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia. Int J Clin Exp Pathol 2014; 7: 4323-4328.
70. Cornet E, Tomowiak C, Tanguy-Schmidt A et al. Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia. Br J Haematol 2014; 166: 390-400.
71. Hisada M, Chen BE, Jaffe ES, Travis LB. Second cancer incidence and causespecific mortality among 3104 patients with hairy cell leukemia: a populationbased study. J Natl Cancer Inst 2007; 99: 215-222.
72. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.